The neuropeptide that controls whether your reproductive system is on or off—and why its ability to trigger ovulation without the most dangerous complication in IVF could reshape fertility medicine

Kisspeptin-10 is a 10-amino-acid neuropeptide that sits at the very top of the reproductive hormone cascade—above GnRH, above LH and FSH, above testosterone and estrogen. It is the endogenous signal that tells GnRH neurons in the hypothalamus to fire, initiating the entire sequence of events that drives puberty, fertility, and sexual function.

The compound's significance was established definitively in 2003, when two independent research groups discovered that humans with loss-of-function mutations in the kisspeptin receptor (GPR54/KISS1R) fail to undergo puberty and are infertile. This genetic proof—you cannot reproduce without kisspeptin signaling—placed the molecule at the center of reproductive neuroendocrinology and launched a clinical development program that has produced some of the most promising IVF safety data in years.

The clinical headline: kisspeptin-54 (the longer active fragment) used as an IVF oocyte maturation trigger produced zero moderate, severe, or critical OHSS cases in a Phase 2 trial involving 60 high-risk women, while maintaining a 45% live birth rate. Given that OHSS is the most feared complication of IVF—occasionally fatal—this is not a trivial finding.

The limitations are equally real. No Phase 3 trial has been completed. Kisspeptin-10 specifically has a half-life of approximately 4 minutes, making it impractical for clinical use outside IV infusion; kisspeptin-54 (half-life ~28 minutes subcutaneous) is the clinical candidate. And the entire kisspeptin clinical program has been driven primarily by one research group at Imperial College London—replication by independent teams is essential before the field can fully commit.

Quick Facts: Kisspeptin-10 at a Glance

What Is Kisspeptin-10?

Pronunciation: KISS-pep-tin ten

Before your brain can produce the hormones that drive puberty, fertility, and sexual function, a single neuropeptide has to give the go signal. That neuropeptide is kisspeptin. It is produced by specialized neurons in the hypothalamus, and its job is to tell GnRH neurons—the cells that control the entire reproductive hormone cascade—to fire. Without kisspeptin, GnRH neurons stay silent. Without GnRH, the pituitary does not produce LH or FSH. Without LH and FSH, the gonads do not produce testosterone or estrogen. The entire system depends on kisspeptin flipping the switch.

Kisspeptin-10 is the minimal active fragment of this signaling molecule—a 10-amino-acid peptide that contains the pharmacophore required for binding GPR54 (also known as KISS1R), the receptor on GnRH neurons. It is derived from kisspeptin-54, the full-length active fragment produced by the KISS1 gene. Both forms activate the same receptor with equal potency in vitro, but kisspeptin-10 has a dramatically shorter half-life (~4 minutes intravenously versus ~28 minutes subcutaneously for kisspeptin-54), which limits its clinical utility.

The compound's importance was cemented in 2003 when two independent research teams—de Roux in France and Seminara at Harvard—simultaneously reported that humans with inactivating mutations in GPR54 fail to undergo puberty and are infertile. This was genetic proof: kisspeptin signaling is not merely involved in reproduction. It is required.

Origins and Discovery

The kisspeptin story begins with a cancer biology lab, not a fertility clinic. The KISS1 gene was discovered in 1996 at Penn State University as a metastasis suppressor—it was named after Hershey's Kisses, a nod to the Hershey, Pennsylvania campus. The gene product, initially called "metastin," was found to suppress tumor metastasis in melanoma cell lines by binding a then-orphan G-protein-coupled receptor, GPR54.

The connection to reproduction came as a complete surprise. In 2003, two research groups—de Roux and colleagues in Paris, and Seminara and colleagues at Harvard—independently discovered that patients with inactivating mutations in GPR54 presented with isolated hypogonadotropic hypogonadism: absent puberty, undetectable gonadotropins, and infertility. Knockout mice confirmed the phenotype. Overnight, a metastasis suppressor gene became the most important discovery in reproductive neuroendocrinology in decades.

The subsequent decade saw an explosion of research into kisspeptin's role in GnRH secretion, puberty onset, and the GnRH pulse generator. The clinical translation has been led primarily by Waljit Dhillo and Ali Abbara at Imperial College London, who conducted the Phase 1 and Phase 2 trials that established kisspeptin as a potential IVF trigger with zero OHSS risk.

The gene's name—derived from a chocolate candy—has become one of endocrinology's most memorable etymological quirks. The original acronym stands for "KiSS-1 metastasis Suppressor," but the chocolate reference has stuck.

Mechanism of Action

The HPG Axis Hierarchy

Kisspeptin sits at the apex of the hypothalamic-pituitary-gonadal (HPG) axis. The signaling cascade is strictly hierarchical: KISS1 neurons produce kisspeptin → kisspeptin activates GPR54 on GnRH neurons → GnRH is released into the hypophyseal portal system → GnRH activates pituitary gonadotrophs → LH and FSH are released → gonads produce sex hormones (testosterone, estrogen, progesterone).

Every drug that manipulates this axis—leuprolide, HCG, HMG, clomiphene—acts downstream of kisspeptin. Kisspeptin is the upstream controller.

GPR54 Signaling

Kisspeptin-10 binds GPR54 (KISS1R) on GnRH neurons with an EC50 of approximately 1 nanomolar. GPR54 is a Gq-coupled GPCR; activation triggers phospholipase C → IP3 + DAG → intracellular calcium release → depolarization of GnRH neurons → GnRH secretion. The signaling is rapid and self-limiting—once kisspeptin is cleared (4 minutes for KP-10, 28 minutes for KP-54), the stimulus ends and GnRH neurons return to baseline.

The GnRH Pulse Generator: KNDy Neurons

The kisspeptin neurons in the arcuate nucleus do not operate alone. They co-express two other neuropeptides—neurokinin B (NKB, stimulatory) and dynorphin (inhibitory)—forming the "KNDy" neuron population that constitutes the molecular GnRH pulse generator.

The pulse cycle works as follows: NKB synchronizes KNDy neuron firing → kisspeptin is released onto GnRH neurons → GnRH pulse occurs → dynorphin terminates the kisspeptin signal → recovery period → cycle repeats approximately every 90 minutes. This pulsatility is critical: continuous GnRH stimulation (as with leuprolide) causes receptor desensitization, while pulsatile GnRH maintains reproductive function.

Sexual Dimorphism

Kisspeptin produces different responses in men and women, reflecting the distinct anatomy of kisspeptin neuron populations. In men, intravenous kisspeptin-10 reliably stimulates a 2–3-fold increase in LH within 30 minutes. In women during the follicular phase, the response is much weaker. During the preovulatory phase, the response is robust—kisspeptin amplifies the endogenous LH surge. This dimorphism reflects estrogen-dependent priming: the AVPV kisspeptin neurons that drive the LH surge are stimulated by estrogen in women, creating a positive feedback loop absent in men.

Why the Short Half-Life Is Actually an Advantage

Kisspeptin's short duration of action—a pharmacological weakness for most applications—is a safety advantage for IVF triggering. HCG, the standard trigger, has a half-life of 24–36 hours, sustaining LHCGR activation long enough to drive the vascular permeability and luteal rescue processes that cause OHSS. Kisspeptin triggers a brief, physiological LH surge that matures oocytes and then stops. No prolonged LHCGR activation. No OHSS.

Key Research Areas and Studies

The IVF OHSS-Free Trigger (Abbara et al., 2015)

The most clinically significant kisspeptin finding to date. Abbara and colleagues randomized 60 women at high OHSS risk to kisspeptin-54 at four dose levels (3.2, 6.4, 9.6, or 12.8 nmol/kg subcutaneous) as their IVF oocyte maturation trigger instead of HCG.

Results: 95% oocyte maturation rate. Biochemical pregnancy rate: 63%. Clinical pregnancy rate: 53%. Live birth rate: 45% per transfer. At the optimal dose (9.6 nmol/kg): 77% clinical pregnancy rate, 62% live birth rate. Most critically: zero moderate, severe, or critical OHSS. The odds ratio for OHSS was 33.6 for HCG, 3.6 for GnRH agonist trigger, and 1.0 for kisspeptin (reference). PMID 26192876

Dose Optimization (Abbara et al., 2017)

A follow-up study tested whether a second dose of kisspeptin-54 could improve oocyte maturation rates. The second dose improved maturation without compromising the safety profile—zero OHSS confirmed. PMID 28854728

Hypothalamic Amenorrhea Reactivation (Jayasena et al., 2014)

Kisspeptin-54 infusion in women with hypothalamic amenorrhea (a condition where chronic stress or energy deficit suppresses the HPG axis) increased LH pulsatility 3-fold versus vehicle. This demonstrated that the dormant HPG axis in hypothalamic amenorrhea can be reactivated by kisspeptin—the axis is suppressed, not broken. PMID 24517142

Healthy Volunteer Physiology (Dhillo et al., 2005)

The first study to characterize kisspeptin-10 effects in humans. Intravenous bolus doses of 0.3–1.0 nmol/kg in healthy men produced dose-dependent LH stimulation. Women in the follicular phase showed minimal response; women in the preovulatory phase showed robust LH/FSH stimulation. This study established the sexually dimorphic response pattern and provided the first human pharmacodynamic data. PMID: PMC3232613

The Genetic Foundation (de Roux, 2003; Seminara, 2003)

The landmark 2003 discoveries by de Roux (Paris) and Seminara (Harvard) that loss-of-function mutations in GPR54 cause hypogonadotropic hypogonadism in humans—confirmed in GPR54 knockout mice—provided the strongest possible mechanistic validation: genetic proof that kisspeptin signaling is required for reproduction. PMID 14614226; 14614222

The OHSS Problem: Why Kisspeptin Matters for IVF

What OHSS Is

Ovarian hyperstimulation syndrome is the most feared complication of IVF. In moderate-to-severe cases, the ovaries enlarge massively, fluid leaks from blood vessels into the abdominal cavity (ascites), the blood becomes dangerously concentrated (hemoconcentration), and the risk of blood clots rises sharply. Severe OHSS can cause kidney failure, respiratory distress, and death. It occurs in 1–5% of IVF cycles with standard HCG trigger, and the risk is highest in the women who need IVF most—young women with polycystic ovary syndrome or high ovarian reserve.

Why HCG Causes OHSS

The standard IVF trigger—HCG at 5,000–10,000 IU—causes OHSS because of its pharmacokinetics. HCG has a half-life of 24–36 hours and potently activates LHCGR on ovarian luteal cells for days after injection. This sustained activation drives vascular endothelial growth factor (VEGF) production from the corpus luteum, increasing capillary permeability and causing fluid shifts. The longer and more intense the LHCGR activation, the greater the OHSS risk.

Why Kisspeptin Does Not

Kisspeptin works upstream. It triggers endogenous GnRH release, which triggers an endogenous LH surge from the pituitary. This LH surge is physiological in amplitude and duration—it lasts hours, not days. When kisspeptin is cleared (28 minutes for KP-54), the stimulus ends, and the LH surge self-terminates. There is no sustained LHCGR activation, no prolonged VEGF production, no OHSS.

This is not a minor pharmacological distinction. It is the difference between a drug that mimics the body's own process and one that overwhelms it.

Claims vs. Evidence

The Human Evidence Landscape

Abbara et al., 2015 (IVF Phase 2 RCT)

Design: Prospective, randomized, dose-ranging. N=60 women at high OHSS risk undergoing IVF. Kisspeptin-54 at 3.2, 6.4, 9.6, or 12.8 nmol/kg SC as oocyte maturation trigger.

Findings: 95% oocyte maturation. Live birth rate 45% per transfer (62% at optimal 9.6 nmol/kg dose). Zero moderate/severe/critical OHSS. OHSS odds ratio: HCG 33.6, GnRHa 3.6, kisspeptin 1.0.

Limitations: Small sample (60 patients). Single center (Imperial College London). No direct randomized comparison to HCG in the same trial. Dose-ranging design means small numbers per dose group.

Abbara et al., 2017 (Dose Optimization)

Design: Phase 2 follow-up. N~30. Second dose of kisspeptin-54 tested to improve oocyte maturation.

Findings: Second dose improved maturation rate. Safety profile maintained—zero OHSS.

Limitations: Small sample. Same research group. Exploratory design.

Jayasena et al., 2014 (Hypothalamic Amenorrhea)

Design: Phase 1/2 crossover. N~10 women with hypothalamic amenorrhea. Kisspeptin-54 infusion vs. vehicle.

Findings: LH pulsatility increased 3-fold during kisspeptin infusion. Demonstrated that HPG axis in HA is suppressed, not broken—kisspeptin can reactivate it.

Limitations: Very small sample. Infusion protocol (not practical for clinical use). No clinical endpoints (menstrual cycle restoration, pregnancy). Proof of concept only.

Dhillo et al., 2005 (Healthy Volunteer Pharmacodynamics)

Design: Phase 1. N~20 healthy men and women. IV kisspeptin-10 bolus at multiple doses.

Findings: Dose-dependent LH stimulation in men (2–3-fold increase within 30 minutes). Weak follicular-phase response in women; strong preovulatory response. First characterization of kisspeptin's sexually dimorphic effects in humans.

Limitations: Small sample. IV route only. Pharmacodynamic study, not therapeutic trial.

de Roux et al. and Seminara et al., 2003 (Genetic Discovery)

Design: Human genetics + animal validation. Families with isolated hypogonadotropic hypogonadism screened for GPR54 mutations. GPR54 knockout mice generated.

Findings: Loss-of-function GPR54 mutations → absent puberty, low gonadotropins, infertility. Knockout mice confirm phenotype. Genetic proof that kisspeptin signaling is required for reproduction.

Limitations: These are genetic discovery papers, not therapeutic trials. They establish mechanism, not clinical utility.

Safety, Risks, and Limitations

Favorable Safety Profile

Across all published human studies, kisspeptin has demonstrated a remarkably benign adverse event profile. Injection site reactions are mild. Flushing, headache, and nausea are occasional and mild. No serious adverse events attributable to kisspeptin have been reported. The defining safety feature—zero OHSS in IVF—is the primary clinical motivation for development.

Desensitization Risk

Continuous kisspeptin administration causes GPR54 desensitization—the receptor internalizes and stops responding, and the HPG axis is paradoxically suppressed. This is the same principle as GnRH agonist desensitization (leuprolide) but one level upstream. This limits kisspeptin to acute or pulsatile dosing; chronic administration would suppress, not stimulate, the reproductive axis.

The Half-Life Problem

Kisspeptin-10's approximately 4-minute half-life makes it impractical for any application requiring sustained effect. Even kisspeptin-54's 28-minute subcutaneous half-life is short by pharmaceutical standards. Long-acting kisspeptin analogs are in preclinical development but none have reached human trials.

Single-Center Limitation

Nearly all clinical kisspeptin data come from the Dhillo/Abbara group at Imperial College London. While the quality of their work is high, independent replication is essential before the field can adopt kisspeptin as a clinical standard. Single-center findings, regardless of rigor, require validation.

Not Commercially Available

Kisspeptin-10 is not available as a consumer product, grey-market research chemical, or compounding pharmacy formulation. It is an investigational compound used exclusively in academic clinical trials. This limits practical relevance for the peptide community.

Legal and Regulatory Status

Investigational Status

Kisspeptin-10 and kisspeptin-54 are investigational compounds. Neither is FDA-approved or approved by any regulatory agency for any indication. No IND filing for Phase 3 trials has been publicly announced as of 2026.

Availability

Not commercially available. Not available from compounding pharmacies or research chemical suppliers in meaningful quantities. Available only through academic clinical trial participation at centers conducting kisspeptin research.

WADA Status

Not explicitly listed on the WADA Prohibited Substances List. However, kisspeptin stimulates LH and FSH release, which could classify it under S2 (Peptide Hormones, Growth Factors) depending on interpretation. Athletes should exercise caution and verify current WADA guidance before any exposure.

Patent Landscape

Kisspeptin analogs and their therapeutic applications are covered by patents held by various academic institutions and pharmaceutical companies. The patent landscape is complex and evolving.

Research Protocols and Formulation Considerations

Research-Grade Material

Kisspeptin-10 is available from research peptide suppliers as a lyophilized powder. Research-grade material is intended for laboratory use only and has not undergone GMP manufacturing.

Pharmacokinetic Profiles

Kisspeptin-10 (IV): Tmax immediate, half-life ~4 minutes. Kisspeptin-54 (SC): Tmax ~30 minutes, half-life ~28 minutes. The dramatic difference in half-life drives the clinical preference for kisspeptin-54 in all therapeutic contexts.

Stability

Kisspeptin peptides are susceptible to enzymatic degradation by matrix metalloproteinases (MMPs) and other serum proteases. Lyophilized powder should be stored at −20°C. Reconstituted solutions are unstable and should be used immediately.

Dosing in Published Research

IVF Trigger (Kisspeptin-54, Clinical Trial Protocol)

The Phase 2 IVF trigger trial used kisspeptin-54 at doses of 3.2, 6.4, 9.6, or 12.8 nmol/kg subcutaneous, administered as a single injection 34–36 hours before egg retrieval. The optimal dose was 9.6 nmol/kg (77% clinical pregnancy rate, 62% live birth rate). A second dose improved oocyte maturation rates.

Healthy Volunteer Studies (Kisspeptin-10)

IV bolus doses of 0.3–1.0 nmol/kg produced dose-dependent LH stimulation in healthy men. These doses are used for pharmacodynamic characterization, not therapeutic purposes.

No Established Clinical Dosing

No FDA-approved dosing exists. All dosing information is derived from investigational clinical trials and should not be extrapolated to clinical practice outside of approved protocols.

Dosing in Self-Experimentation Communities

[Critical Disclaimer — Community Dosing] The following section documents the current state of community use. Kisspeptin-10 is not available in the self-experimentation community in any meaningful way. Unlike compounds such as BPC-157 or Melanotan II, there is no established grey-market kisspeptin supply chain. No community dosing protocols exist. The compound's extremely short half-life, lack of commercial availability, and purely investigational status limit it to academic research settings. Peptidings includes this section for completeness, not because community use occurs.

Why Community Use Is Absent

Three factors prevent community adoption. First, kisspeptin-10's 4-minute half-life makes subcutaneous self-injection pointless—the compound would be cleared before it could produce a sustained effect. Second, reliable sources of GMP-quality kisspeptin are not available outside clinical trials. Third, the compound's mechanism (stimulating endogenous LH rather than providing exogenous hormone) offers no advantage over cheaper, more available alternatives like HCG or clomiphene for the use cases the community cares about.

Combination Stacks

Research into Kisspeptin-10 combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.

If you are considering combining Kisspeptin-10 with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.

Frequently Asked Questions

Related Compounds: How Kisspeptin-10 Compares

Edit

Compound	Type	Evidence Tier	Verdict	Mechanism	Primary Use Case	Human Data	FDA Status	WADA Status	Key Limitation
PT-141 (Bremelanotide)	Cyclic heptapeptide; MC3R/MC4R agonist; ~1,025 Da	Tier 1 — Approved Drug	Strong Foundation	MC4R agonism in hypothalamus → central sexual arousal pathway; 5,000-fold MC4R:MC1R selectivity (no pigmentation)	HSDD in premenopausal women (FDA-approved); off-label male sexual dysfunction	~3,000 across Phase 1–3 (RECONNECT N=1,247; BLOOM N=1,247)	FDA-approved 2019 (Vyleesi, Palatin/Amag)	Prohibited (S2, males only)	43% nausea rate; no postmenopausal efficacy (AFTERGLOW failed); SC injection only; limited long-term data
Melanotan II	Cyclic heptapeptide; non-selective melanocortin agonist; ~1,024 Da	Tier 3 — Pilot / Limited Human Data	Eyes Open	Non-selective MC1R/MC3R/MC4R/MC5R agonism → tanning (MC1R) + sexual arousal (MC4R) + appetite suppression (MC4R)	Tanning; sexual arousal; appetite suppression (all off-label/underground)	1 small Phase 2 (Wessells, N=12, erectile response); ~20 Phase 1 PK	Not approved; development abandoned ~2000	Prohibited (S2)	Non-selective → uncontrolled pigmentation, nevi darkening, unresolved melanoma risk; zero Phase 3 data; grey-market quality variable
Leuprolide	Nonapeptide; GnRH superagonist; 1,209 Da	Tier 1 — Approved Drug	Strong Foundation	GnRH-R super-agonism → initial flare (LH/T surge) → receptor desensitization → chemical castration; Kd ~0.1 nM	Prostate cancer; endometriosis; uterine fibroids; central precocious puberty	500,000+ in registries; dozens of Phase 3 RCTs; decades of pharmacovigilance	FDA-approved 1985 (Lupron, Eligard, multiple generics)	Prohibited (S2)	Hot flashes 60–70%; bone density loss 2–3%/year; mood changes; temporary symptom flare at initiation
HCG (Human Chorionic Gonadotropin)	Glycoprotein hormone (~36,700 Da); LH/CG receptor agonist	Tier 1 — Approved Drug	Strong Foundation	LHCGR agonism → Leydig cell testosterone production; oocyte maturation trigger; 6–10× more potent than LH	Ovulation induction (IVF); male hypogonadism; fertility preservation during TRT; cryptorchidism	500,000+ across decades; Cochrane reviews for IVF; multiple RCTs	FDA-approved 1967 (Pregnyl, Novarel, Ovidrel)	Prohibited (S2, males only)	OHSS risk 1–5% in IVF; removed from 503A compounding (2020 BPCIA); debunked for weight loss
HMG (Human Menopausal Gonadotropin)	Glycoprotein mixture (FSH + LH/HCG activity); urinary-derived	Tier 1 — Approved Drug	Strong Foundation	Dual FSH (follicular growth) + LH activity (theca steroidogenesis); two-cell two-gonadotropin model	Controlled ovarian stimulation (IVF); spermatogenesis induction in HH	4,500+ across meta-analyses and RCTs; equivalent to rFSH for pregnancy rates	FDA-approved (Menopur, Ferring)	Prohibited (S2)	OHSS risk comparable to rFSH; urinary-derived (batch variability); requires specialist supervision
Kisspeptin-10	Decapeptide; GPR54 (KISS1R) agonist; ~1,302 Da	Tier 2 — Clinical Trials	Reasonable Bet	GPR54 agonism on hypothalamic GnRH neurons → endogenous GnRH/LH release; master upstream regulator of HPG axis	IVF oocyte maturation trigger (OHSS-free); hypothalamic amenorrhea; HPG axis reactivation	~145 across Phase 1–2 (IVF RCT N=60; HA studies; healthy volunteers)	Not approved (investigational; Phase 2 completed)	Not explicitly listed	~4-minute half-life (KP-10); Phase 3 pending; KP-54 preferred for clinical use; no chronic dosing data
Oxytocin	Cyclic nonapeptide; OXTR agonist; 1,007 Da	Tier 1 — Approved Drug	Strong Foundation	OXTR (Gq/Gi-coupled) → uterine contraction (peripheral) + social cognition/bonding/stress modulation (central)	Labor induction/augmentation; postpartum hemorrhage; milk letdown; investigational: autism, anxiety, PTSD	500,000+ obstetric use; autism RCT N=250 (negative); psychiatric meta-analyses	FDA-approved (Pitocin; Syntocinon outside US)	Not prohibited	Uterine hyperstimulation (dose-dependent); autism RCT negative; neuropsych results inconsistent; short half-life (3–5 min IV)

↑ Back to Contents

Summary of Key Findings

Kisspeptin-10 sits at the apex of reproductive neuroendocrinology—the master upstream regulator of GnRH secretion, genetically validated as essential for puberty and fertility. Its clinical promise centers on one compelling finding: when kisspeptin-54 was used as an IVF oocyte maturation trigger in a Phase 2 trial of 60 high-risk women, zero developed moderate, severe, or critical OHSS, while maintaining a 45% live birth rate. In a field where OHSS is the most feared complication—and where the standard trigger (HCG) causes it in 1–5% of cycles—this is a signal that cannot be ignored.

The mechanistic foundation is as strong as it gets. Loss-of-function mutations in GPR54 cause hypogonadotropic hypogonadism in humans—genetic proof that kisspeptin signaling is required for reproduction. The KNDy neuron circuitry that generates GnRH pulsatility is well-characterized. The Phase 1 pharmacodynamic data in healthy volunteers confirm that exogenous kisspeptin stimulates LH release in humans.

The limitations are equally clear. No Phase 3 trial has been completed. The entire clinical dataset comes primarily from one research group at Imperial College London. Kisspeptin-10 specifically has a 4-minute half-life that makes it impractical outside IV infusion; kisspeptin-54 is the clinical candidate. Long-acting analogs are in early development but have not reached human testing. And the compound is not commercially available.

Kisspeptin is a Reasonable Bet because the mechanism is genetically validated, the clinical signal is real, and the safety advantage (zero OHSS) addresses an unmet need in IVF. It is not yet a Strong Foundation because the Phase 3 data needed to change clinical practice do not exist.

Verdict Recapitulation

Kisspeptin-10 earns Tier 2 and a Reasonable Bet verdict because it has been tested in multiple Phase 1 and Phase 2 clinical trials with consistent, promising results—including zero OHSS in IVF triggering—backed by one of the strongest mechanistic foundations in peptide pharmacology (genetic proof of requirement for reproduction). The absence of Phase 3 data, single-center predominance, and pharmacokinetic challenges prevent a higher rating.

For readers considering Kisspeptin-10, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.

Where to Source Kisspeptin-10

Further Reading and Resources

If you want to go deeper on Kisspeptin-10, the evidence landscape for sexual health & hormonal peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

ON PEPTIDINGS

• Sexual Health & Hormonal Research Hub — Overview of all compounds in this cluster
• Reconstitution Guide — How to properly prepare injectable peptides
• Storage and Handling Guide — Proper storage to maintain peptide stability
• About Peptidings — Our editorial methodology and evidence framework

EXTERNAL RESOURCES

• PubMed: Kisspeptin-10 — All indexed publications
• ClinicalTrials.gov — Active and completed trials

Selected References and Key Studies

1. Abbara A, Jayasena CN, Christopoulos G, et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of ovarian hyperstimulation syndrome (OHSS) during in vitro fertilization (IVF) therapy. Journal of Clinical Endocrinology & Metabolism, 2015;100(9):3322–3331. PMID 26192876
2. Abbara A, Clarke S, Islam R, et al. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. Human Reproduction, 2017;32(9):1915–1924. PMID 28854728
3. Jayasena CN, Abbara A, Veldhuis JD, et al. Increasing LH pulsatility in women with hypothalamic amenorrhoea using intravenous infusion of kisspeptin-54. Journal of Clinical Endocrinology & Metabolism, 2014;99(6):E953–E961. PMID 24517142
4. Dhillo WS, Chaudhri OB, Patterson M, et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. Journal of Clinical Endocrinology & Metabolism, 2005;90(12):6609–6615. PMID: PMC3232613
5. de Roux N, Genin E, Carel JC, et al. Hypogonadotropic hypogonadism due to loss of function of the KiSS1-derived peptide receptor GPR54. Proceedings of the National Academy of Sciences, 2003;100(19):10972–10976. PMID 14614226
6. Seminara SB, Messager S, Chatzidaki EE, et al. The GPR54 gene as a regulator of puberty. New England Journal of Medicine, 2003;349(17):1614–1627. PMID 14614222

---